English | Español

Bristol-Myers Squibb
Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA
Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results
Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients
Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma
Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients
Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending
Patient Daily | Aug 1, 2025

Executive director of ASAP 340B: ‘The second largest drug discount program in the country doesn't have basic transparency’
Patient Daily | Aug 4, 2025

Founder of ReKlaim Health on 340B: ‘They pocket the difference, bill insurers and patients full price and call it charity care’
+ Pharmaceuticals
Patient Daily | Aug 5, 2025

American Lung Association study urges schools to prioritize clean classroom air
Patient Daily | Aug 7, 2025

Dallas Breathe Free Sinus & Allergy Centers earns 4.8-star rating from 670 Google reviews